Clinical Trials

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.

AB Science has secured a US patent until 2042 for masitinib, a targeted therapy for advanced prostate cancer, offering new hope where few options exist.

A new network aims to speed up clinical trials by recruiting patients from med spas and longevity clinics. Is this the future of medicine or a risky new frontier?

A key regulatory win in Abu Dhabi opens a new international front for NeOnc's war on brain tumors, backed by novel science and significant insider buying.

A new partnership between Medventions and Mitacs aims to fix Canada's innovation gap by embedding engineers directly into clinics. Here's how it works.

An Israeli biotech just published a patent for a 'mucoadhesive' gel that makes drugs stick inside the nose. It's a key step in a multi-billion dollar race.

Rare complete responses in deadly pancreatic cancer hint at a powerful new synergy, but can Elicio Therapeutics secure the funding to prove its theory?

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

21 doctors from one practice in a "Top Doctors" Hall of Fame is a headline. But what does it reveal about building trust and innovation in cancer care?

A new AU$481M deal with Everest Medicines brings a promising FSGS drug closer to 1M Asian patients, part of a larger, de-risked global strategy.

Verastem Oncology's new drug enters a pivotal trial for pancreatic cancer, targeting a notorious mutation with a novel dual-action mechanism.

A new alliance between Sun Life and Medzown moves beyond financial safety nets, using AI to steer patients to clinical trials and reshape corporate healthcare.

A new approval in Abu Dhabi for NeOnc's NEO212 isn't just a clinical step; it's a strategic play in the high-stakes world of brain cancer therapy.

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

Adial Pharmaceuticals pivots from addiction to inflammation, securing $32M and poaching Azora's leadership to drive its new ulcerative colitis drug, AT177.

A new partnership between Innoviva and Dr. Reddy's aims to bring a vital antibiotic, XACDURO®, to regions where a deadly hospital infection is rampant.

Acumen Pharmaceuticals unveils two new candidates using a novel technology to deliver therapies directly to the brain, promising a more effective fight against AD.